Array Biopahrma Inc. ( NASDAQ:ARRY ) has agreed to acquire worldwide rights for Novartis cancer drug, encorafenib (LGX818), an investigational BARF inhibitor in its late stage clinical trials. The company stock shot up over 40% on Friday, following ... Bidness Etc, 20 hours ago
United States : ARRAY BIOPHARMA to acquire global ENCORFENIB rights from NOVARTIS [TendersInfo (India)] - Pharmacy Choice, 7 hours ago
Array to acquire Novartis BRAF inhibitor encorafenib (LGX818) - Center Watch, 20 hours ago
A revived GlaxoSmithKline is back on target with Novartis deal - so are the shares in Britain's biggest drug firm now worth a punt?
By Published: 1 View comments After what many would acknowledge as an annus horribilis, GlaxoSmithKline chief executive Sir Andrew Witty must have been relieved to see the back of 2014. It was a year in which the pharmaceutical firm's shares ...This is Money, 21 hours ago NOVARTIS : Daily Mail, London, Investment Extra column 4 Traders, 1 day ago INVESTMENT EXTRA: A revived GlaxoSmithKline is back on target This is Money, 1 day ago Daily Mail, London, Investment Extra column [Daily Mail, London] BusinessWeek, 1 day ago
News Editor The FDA approves Novartis' (NYSE:NVS) Bexsero, a vaccine to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroup B in individuals ages 10 through 25. This approval, including Pfizer's clearance in ...Seeking Alpha, 1 day ago Novartis: CHMP Adopts Positive Opinion For Jakavi - Quick Facts RTTNews.com, 2 days ago Array buying Novartis BRAF inhibitor for (almost) no money down Scrip, 1 day ago News Scan for Jan 23, 2015 Centre For Infectious Disease Research and Policy, 1 day ago
- US-based biopharmaceutical company Array BioPharma Inc According to the parties, this agreementis conditional on the closing of transactions announced by Novartis and GlaxoSmithKline PLC onApril 22, 2014, which are expected to close in the first ...BusinessWeek, 1 day ago Array Biopharma : BRIEF: Shares of Boulder-based Array jump after drug agreement with Novartis 4 Traders, 1 day ago Array Biopharma : shares jump after drugmaker details Novartis deal 4 Traders, 1 day ago Array BioPharma shares jump on news of Novartis cancer-drug deal Yahoo! News, 15 hours ago
Despite an expected dip in profit, analysts are generally optimistic about Novartis as it prepares to reports its fourth-quarter earnings on Tuesday, January 27, 2015. The consensus earnings per share estimate is $1.13 per share. The consensus ...Forbes.com, 1 day ago
Jan 22 (Reuters) - Novartis will review its Swiss cost base after the country's central bank scrapped a cap on the franc last week, sending the currency soaring, the Swiss drugmaker's chief executive said on Thursday. "We'll have to take a hard ...Reuters, 2 days ago Novartis AG CEO Taking a Hard Look at Swiss Costs, Possible Bolt-On Acquisitions BioSpace, 1 day ago Video: We are funding part of ACA: Novartis CEO NBCNews.com, 2 days ago Novartis CEO says reviewing Swiss costs on franc shock The Gulf Today, 1 day ago
After closing Wednesday at $98.75, Novartis AG (http://www.marketintelligencecenter.com/symbol/NVS"NVS) presents an attractive opportunity to get a 2.90% return in just 176 days, which is an annualized return of 6.02% (for comparison purposes only).Individual.com, 2 days ago Novartis AG (NVS) Showing Bullish Technicals With Resistance At $102.68 Individual.com, 4 days ago
Jan 23 (Reuters) - Aspen Pharmacare Holdings Ltd * Acquisition of rights to an anti-coagulant product from Novartis * Has entered into an agreement with Novartis AG in terms of which it will acquire rights to Mono-Embolex * Deal ...Reuters Africa, 2 days ago Aspen Pharmacare Ltd. Grabs Rights to Novartis AG's Mono-Embolex for $142.3 Million BioSpace, 1 day ago
Novartis (NYSE:NVS) traded in a range yesterday that spanned from a low of $95.86 to a high of $97.11. Yesterday, the shares fell 1.9%, which took the trading range below the 3-day low of $98.10 on volume of 3.0 million shares. Often times after ...Individual.com, 2 days ago SmarTrend Watching for Potential Rebound in Shares of Novartis After 1.93% Loss Comtex SmarTrend, 2 days ago
The Federal Trade Commission has finally approved the joint venture of Novartis AG (ADR) ( NYSE:NVS ) and GlaxoSmithKline Plc (ADR) ( NYSE:GSK) in consumer health products, and Novartis has agreed to divest its Habitrol line of nicotine patches. ...Bidness Etc, 3 days ago FTC Approves Novartis/GSK OTC Venture But Novartis Must Divest Nicotine Patch Biz Pharmaceutical Manufacturing Magazine, 2 days ago
on your WebpageAdd Widget >Get your members hooked!